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AbstrAct
Objective to compare efficacy and safety of 
subcutaneous sarilumab 200 mg and 150 mg every 2 
weeks plus conventional synthetic disease-modifying 
antirheumatic drugs (+csDMarDs) versus other targeted 
DMarDs+csDMarDs and placebo+csDMarDs, in 
inadequate responders to csDMarDs (csDMarD-ir) or 
tumour necrosis factor α inhibitors (tnFi-ir).
Methods Systematic literature review and network meta-
analyses (nMa) conducted on 24 week efficacy and safety 
outcomes: Health assessment Questionnaire Disability 
index, modified total sharp score (mtSS, including 
52 weeks), american college of rheumatology (acr) 
20/50/70, european league against rheumatism Disease 
activity Score 28-joint count erythrocyte sedimentation 
rate (DaS28)<2.6; serious infections/serious adverse 
events (including 52 weeks).
Results 53 trials were selected for nMa. csDMARD-IR: 
Sarilumab 200 mg+csDMarDs and 150 mg+csDMarDs 
were superior versus placebo+csDMarDs on all outcomes. 
against most targeted DMarDs, sarilumab 200 mg 
showed no statistically significant differences, except 
superiority to baricitinib 2 mg, tofacitinib and certolizumab 
on 24 week mtSS. Sarilumab 150 mg was similar to all 
targeted DMarDs. TNFi-IR: Sarilumab 200 mg was similar 
to abatacept, golimumab, tocilizumab 4 mg and 8 mg/kg 
intravenously and rituximab on acr20/50/70, superior to 
baricitinib 2 mg on acr50 and DaS28<2.6 and to abatacept, 
golimumab, tocilizumab 4 mg/kg intravenously and rituximab 
on DaS28<2.6. Sarilumab 150 mg was similar to targeted 
DMarDs but superior to baricitinib 2 mg and rituximab on 
DaS28<2.6 and inferior to tocilizumab 8 mg on acr20 
and DaS28<2.6. Serious adverse events, including serious 
infections, appeared similar for sarilumab versus comparators.
Key messages
What is already known about this subject?
 ► the addition of bDMarDs to csDMarDs is rec-
ommended in guidelines from acr and eUlar for 
achieving remission or reducing disease activity in 
patients with ra who have an inadequate response 
to csDMarDs alone.
 ► given the variety of treatments currently available 
for ra, a comprehensive evaluation of the compar-
ative effectiveness and safety of sarilumab against 
other DMarDs is necessary to inform treatment de-
cisions and health technology assessments, as well 
as to guide evidence-based medicine.
What does this study add?
 ► in the absence of head-to-head trials, network 
meta-analysis can provide estimates of comparative 
effectiveness via the combined evaluation of direct 
and indirect trial evidence.
 ► For inadequate responders of csDMarDs or tumour 
necrosis factor inhibitors, sarilumab 150 mg and 
200 mg subcutaneous every 2 weeks plus csD-
MarDs had superior efficacy and similar safety ver-
sus continued use of csDMarDs alone. Sarilumab 
150 mg and 200 mg had at least similar efficacy ver-
sus all other comparable doses of targeted DMarDs 
added to csDMarDs.
How might this impact on clinical practice?
 ► Physicians may use these results from this clinical 
study to inform treatment decisions for patients with 
ra.
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Conclusions results suggest that in csDMarD-ir and tnFi-ir (a smaller 
network), sarilumab+csDMarD had superior efficacy and similar safety 
versus placebo+csDMarDs and at least similar efficacy and safety versus 
other targeted DMarDs+csDMarDs.
InTROduCTIOn
The addition of biological disease-modifying antirheu-
matic drugs (bDMARDs) (including tumour necrosis 
factor-α inhibitors (TNFi), T cell costimulatory inhibitors, 
anti-B cell agents and anti-interleukin-6 receptor (anti-
IL-6R) monoclonal antibodies) or targeted synthetic 
DMARDs (tsDMARDs) to conventional synthetic 
DMARDs (csDMARDs) is recommended in guidelines 
issued by both The American College of Rheumatology 
(ACR)1 and the European League Against Rheumatism 
(EULAR)2 for achieving remission or reducing disease 
activity in patients with rheumatoid arthritis (RA) who 
have inadequate response (IR) to csDMARDs alone. Sari-
lumab is a human immunoglobulin (Ig) G1 anti-IL-6Rα 
monoclonal antibody for the treatment of RA as mono-
therapy or combination therapy with csDMARDs.3–6 
Given the variety of treatments currently available for 
RA, a comprehensive evaluation of the comparative effec-
tiveness and safety of sarilumab against other DMARDs is 
necessary to inform treatment decisions and health tech-
nology assessments, as well as to guide evidence-based 
medicine.7
Active comparator randomised controlled trials 
(RCTs) are the gold standard methodological approach 
for comparative efficacy.8 However, research is mainly 
characterised by placebo-controlled studies, while head-
to-head trials are not readily available. In the absence 
of head-to-head studies, network meta-analysis (NMA) 
can provide estimates of comparative effectiveness via 
the combined evaluation of direct and indirect trial 
evidence;9–11 treatments can then be compared with each 
other via common comparators.
This NMA was conducted to evaluate the comparative 
efficacy and safety of subcutaneous (SC) sarilumab at 
doses of 150 mg and 200 mg, administered every 2 weeks 
(q2w) and added to csDMARDs. Sarilumab was evalu-
ated versus other licensed treatments for RA, including 
csDMARDs, bDMARDs and tsDMARDs, at recommended 
doses for the treatment of RA, in two groups of patients: 
csDMARD-IR and TNFi-IR. The csDMARD-IR popu-
lation was studied separately for combination therapy 
and monotherapy. The focus of the current NMA is on 
patients receiving an addition of a bDMARD or tsDMARD 
to their existing csDMARD treatment regimen.
MeTHOds
A systematic literature review (SLR) and NMA were 
conducted following methods in line with PRISMA 
guidelines12 and recommended in the current National 
Institute for Health and Care Excellence (NICE) spec-
ification for manufacturer and sponsor submission of 
evidence13 and the 2016 NICE technology appraisal 
of adalimumab, etanercept, infliximab, certolizumab 
pegol, golimumab, tocilizumab and abatacept for RA.14
study selection
Searches for the SLR were conducted in MEDLINE, 
EMBASE, Cochrane databases (all with no backwards 
time limit) and conference proceedings (since 2013), 
on evidence published until 6 December 2016, and 
studies were selected according to predefined PICOS 
(population/intervention/comparator/outcome/
study design) criteria12 13 15 16 (table 1). All titles, 
abstracts and articles were screened independently 
by two researchers, with study selection following 
published best practice guidelines for NMA.13 15 16 
Data on study design, patient characteristics, efficacy, 
safety and patient-reported outcomes (PROs) at the 
time points 12 (±4), 24 (±4) and 52 (±8) weeks for all 
studies (except open-label extensions) were extracted 
independently by two reviewers in a predefined data 
extraction process.
Evidence for the NMA was filtered for drugs licensed 
for RA at doses approved in Europe, the USA and 
Canada. In addition, the investigational drug barici-
tinib 2 mg daily (qd) and 4 mg qd combined with meth-
otrexate/csDMARD were included as this agent was 
at advanced regulatory stages at the time of analyses. 
Rituximab (currently only licensed for the TNFi-IR 
population) was included for the csDMARD-IR popu-
lation in the interest of providing a bridge for rele-
vant comparators, while anakinra was excluded due to 
its uncommon use, in addition to its reported limited 
effectiveness relative to other biologics.1
All trials comparing one intervention of interest with 
at least one other intervention of interest or meth-
otrexate or ≥1 csDMARD(s) were considered in the 
evidence base. Small studies (less than 30 patients per 
arm) were excluded from the evidence base on the basis 
that small studies have been shown to distort meta-anal-
yses.17 Studies that did not report any outcomes of 
interest were also excluded.
treatment categorisation
Treatment categorisation was based on grouping all the 
available treatments for inclusion in the networks (table 2). 
Methotrexate and csDMARD used as background therapies 
were considered similar and grouped, while randomised 
treatment groups with one csDMARD+methotrexate were 
separated from those including two csDMARDs+metho-
trexate. Different licensed dosages and different routes of 
administration (eg, intravenous (IV) vs SC delivery) of the 
same treatment were pooled in many cases, on the basis 
of evidence of equivalence (table 2). These decisions were 
explored by examining forest plots of the OR for ACR20 
at 24 weeks in individual studies by group of interventions. 
If the confidence intervals were overlapping (eg, for inflix-
imab studies), the doses were pooled. The validity of the 
decisions was also confirmed via clinician input.
 o
n
 18 M
arch 2019 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000798 on 18 February 2019. Downloaded from
 
3choy e, et al. RMD Open 2019;5:e000798. doi:10.1136/rmdopen-2018-000798
Rheumatoid arthritis
Table 1 Population/intervention/comparator/outcome/study design and search criteria for the systematic review
Criteria Inclusion
Study design Randomised controlled trials above phase I
(including crossover studies up to time of crossover)
Population  ► Adult patients (18 years or older) with moderately to severely active rheumatoid arthritis 
who have had inadequate response to one or more csDMARD
 ► Adult patients (18 years or older) with moderately to severely active rheumatoid arthritis 
who have had inadequate response to one or more anti-tumour necrosis factors
Treatment/intervention The following interventions are of interest at any dosage or administration type:
 ► Sarilumab (REGN88, 
SAR153191)
 ► Adalimumab (Humira)
 ► Certolizumab (Cimzia)
 ► Etanercept (Enbrel)
 ► Golimumab (Simponi)
 ► Infliximab (Remicade)
 ► Abatacept (Orencia)
 ► Rituximab (MabThera/
Rituxan)
 ► Tocilizumab (RoActemra/
Actemra)
 ► Tofacitinib (Xeljanz)
 ► SB4 (Samsung Bioepis)
 ► GP2015 (Sandoz)
 ► ABP501 (Amgen)
 ► BI695501 (Boehringer)
 ► SB5 (Samsung Bioepis)
 ► Remsima (CT-P13)
 ► SB2 (Samsung Bioepis)
 ► Inflectra (CT-P13)
 ► Flixabi (Biogen)
 ► Rituxan (GP2013)
 ► Baricitinib (LY3009104, 
INCB028050)
Comparator Placebo or any of the above listed treatments in combination with a csDMARD(s) (ie, 
methotrexate, leflunomide, hydroxychloroquine, minocycline, sulfasalazine, azathioprine, 
sodium aurothiomalate and auranofin) or csDMARD as monotherapy or in combination with 
other csDMARD(s).
Outcomes Efficacy, safety and patient-reported outcomes at 24 weeks (±4 weeks) and 52 weeks (±8 
weeks).
Time No limit on time horizon.
Language English language.
csDMARD, conventional disease-modifying antirheumatic drugs.
Outcomes examined for the NMA included: ACR 20%, 
50% and 70% (ACR20/50/70) response criteria, EULAR 
Disease Activity Score 28-joint count (DAS28) remission 
(defined as DAS28 erythrocyte sedimentation rate (ESR) 
or C reactive protein (CRP) <2.6), Health Assessment 
Questionnaire Disability Index (HAQ-DI) change from 
baseline (CFB), modified total sharp score (mTSS) CFB, 
incidence of serious infections (SIs) and serious adverse 
events (SAEs). However, as different studies reported 
different scores for radiographic progression, for example, 
van der Heijde mTSS or Genant total sharp score, only the 
studies reporting van der Heijde mTSS were considered for 
this endpoint; the other scoring systems were deemed to be 
incomparable.18
All efficacy outcomes were examined at 24 weeks; mTSS 
was also evaluated at week 52 in addition to week 24; SI and 
SAE in the csDMARD-IR and TNFi-IR populations were 
evaluated at week 24 and week 52, respectively.
network meta-analysis
nMa feasibility assessment
The sufficiency of the evidence base to draw feasible 
networks was assessed for all outcomes of interest. The 
exchangeability assumption is critical and requires that 
selected trials measure the same underlying relative treat-
ment effects. Deviations to this assumption can be evaluated 
through two metrics: (1) heterogeneity (ie, evaluation of 
comparability in characteristics and results across included 
studies) and (2) consistency (ie, evaluation of consistency 
between direct and indirect evidence).
A high level of variability in placebo response was 
observed across both the csDMARD-IR and TNFi-IR 
networks. Such heterogeneity of response in the placebo 
arms of the studies (ie, placebo+csDMARDs in combina-
tion studies) has previously been noted in other RA clinical 
studies and by NICE.19 Therefore, to account for the vari-
ation in the placebo responses across studies, alternative 
analytic methods were applied in the present NMA.
For the larger csDMARD-IR combination network, NMA 
with regression on baseline risk (BR-NMA) was used to adjust 
for variability in placebo responder rates. The BR-NMA 
model is similar to the conventional NMA method with the 
addition of an adjustment for the baseline odds and better 
adjusts for potential bias introduced by variability in the 
placebo responder rates across the different studies. This 
approach is recommended by NICE Decision Support Unit 
(DSU) guidelines.20 However, as only binary outcomes have 
sufficient data to facilitate the BR-NMA, NMA with regres-
sion on baseline risk for placebo response was conducted 
on binary outcomes (ACR20/50/70 and DAS28 remission) 
as the base case model for the csDMARD-IR population.
For any regression, a relatively high number of studies 
per covariate is necessary, otherwise the model is unlikely 
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Table 2 Key features of patient demographics and baseline data for selected studies
csDMARD-IR
Patient demographics
Age Mean ages were similar between all studies (and study arms) ranging from 46.7 years35 to 57.3 
years36–38
Sex In all trials except ATTEST, the majority of patients were female
Ethnicity In those trials reporting ethnicity, the majority of the patients were Caucasian, although in seven 
trials, the entire population was Asian35 39–45
Patient baseline clinical status
Weight Mean weight ranged from 52.9 kg (J-RAPID) to 82 kg (MEASURE)
Proportion rheumatoid 
factor positive
The proportion of patients who were rheumatoid factor positive was above 60% in all studies 
reporting this value, except for the ASSET trial (55.6% for abatacept intravenous 8 mg/kg 
q4w+methotrexate)
Disease duration Mean disease duration ranged widely, from 6 months (SWEFOT) to 13.1 years (ARMADA)
Tender joint count Mean tender joint count ranged from 3 (ENCOURAGE) to 35 (DANCER) on the 68-count scale
Swollen joint count Mean swollen joint count ranged from 3.2 (CERTAIN) to 24.0 (ATTRACT) on the 66-count scale
Prior DMARD use Prior DMARD use ranged from 1.1 (STAR) to 3.1 (ARMADA) in 26 studies that reported prior 
DMARD use
TNFi-IR
Patient demographics
Age Mean ages were similar across the patient populations, ranging from 50.94 years (RADIATE) to 
58.2 years (ORAL Step)
Sex The majority of patients were female
Ethnicity In those trials reporting ethnicity, the majority of the patients were Caucasian
Patient baseline clinical status
Weight Two studies reported mean weight from 78.2 kg (ATTAIN) to 79.4 kg (TARGET)
Proportion rheumatoid 
factor positive
The proportion of patients who were rheumatoid factor positive varied from 51% (Manders 2014) 
to 79% (TARGET, RADIATE and REFLEX)
Disease duration Mean disease duration ranged from 5.6 years (Manders 2014) to 14.0 years46 (RA-BEACON)
Tender joint count Mean tender joint count ranged from 27.6 (ORAL step) to 33.9 (REFLEX)
Swollen joint count Mean swollen joint count ranged from 6 (RA-BEACON) to 23.4 (REFLEX)
Prior DMARD use In the two studies (REFLEX and RADIATE) reporting prior csDMARD use, the use varied from 1.9 
(RADIATE) to 2.6 (REFLEX)
Baseline disease severity Mean DAS28 differed between the studies. For the csDMARD or methotrexate arms, the mean 
baseline DAS28-CRP ranged from 5.4 (ORAL Step) to 6.9 (REFLEX); the DAS28-ESR from 4.7 
(Manders et al 2015) to 6.5 (ORAL Step) and the DAS28-unspecified from 6.5 (ATTAIN) to 6.8 
(RADIATE)
CRP, C reactive protein; csDMARD, conventional disease-modifying antirheumatic drugs;DAS-28, Disease Activity Score 28-joint count; 
ESR, erythrocyte sedimentation rate; IR, inadequate response; TNF, tumour necrosis factor inhibitor.
to converge and less precise estimations are produced, 
resulting in wide credible intervals around the point esti-
mates. In previous NMAs, prior to the publication of 
NICE guidance to address the problem of high variation 
of study effects, a conventional OR approach was applied, 
which gave inconsistent results (eg, this may have overes-
timated relative effect for treatment with studies having 
low study effect and reverse).19 Therefore, for the smaller 
TNFi-IR network, an alternative method of NMA based 
on risk differences (RD-NMA) was adopted,13 21 whereby 
a risk difference scale is used in place of a log OR scale; 
responder levels are treated as continuous outcomes 
following a normal distribution. This approach was based 
on Spiegelhalter and colleagues21 and practical guidance 
in the NICE DSU Guidance on Network Meta-Analysis.20
For safety outcomes, a conventional OR model was 
used for SAE in the csDMARD combination population, 
and for SI and SAE in the TNFi-IR population. RD-NMA 
was applied for SI in the csDMARD-IR population due to 
convergence issues in the OR model.
Bayesian nMa
The selected outcomes, that is, relative efficacy and safety of 
the treatments of interest, were evaluated using a Bayesian 
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NMA approach,16 22 23 which involves a likelihood distri-
bution, a model with parameters and prior distributions 
for these parameters. In this analysis, a linear model with 
normal likelihood distribution was used for continuous 
outcomes, and a binomial likelihood with a log link for the 
dichotomous outcomes.20 21 Flat (non-informative) prior 
distributions were assumed for nearly all outcomes so as not 
to influence the observed results by the prior distribution; 
this approach was consistent with NICE guidelines.20 Prior 
distributions of the baseline treatments and relative treat-
ment effects were normal, with zero mean and variance of 
10 000, while a uniform distribution with range zero to five 
was used as the prior of the between-study SD.
For most outcomes, random-effects and fixed-effects 
models were evaluated to allow for heterogeneity of treat-
ment effects between studies. Random-effects models were 
applied where sufficient data were available; where the 
number of studies was smaller (eg, most outcomes in the 
TNFi-IR population), it was necessary to use the fixed-ef-
fects model, as random-effects models would provide unre-
alistically wide credible intervals for such limited datasets. 
Where both random-effects and fixed-effects models were 
run, the choice of base case was informed by Deviance 
Information Criterion (DIC) values.21 Total residual devi-
ance (compared against the number of fitted data points) 
was also considered in model selection, indicating the 
adequacy of the model to the data. In addition, the consis-
tency of modelled data with directly reported trial results 
was also taken into consideration in selecting the preferred 
model.
Posterior densities for unknown parameters were esti-
mated using Markov chain Monte Carlo simulations. All 
results for conventional OR and RD-NMA were based on 
100 000 iterations on three chains, with a burn-in of 20 000 
iterations. All results for BR-NMA models were based on 
70 000 iterations on three chains, with a burn-in of 15 000 
iterations. Convergence was assessed by visual inspection 
of trace plots. The accuracy of the posterior estimates was 
assessed using the Monte Carlo error for each parameter 
(Monte Carlo error <1% of the posterior SD). All models 
were implemented using WinBUGS.14
Bayesian NMA provided posterior distributions of the 
relative treatment effects between interventions and the 
probability that one treatment is better than another for 
each outcome of interest. The results of the NMA are 
presented in terms of ‘point estimates’ (median of poste-
rior) for the relative treatment effects, along with the 95% 
credible intervals.
Scenario analyses
A series of scenario analyses were conducted whereby 
outlier studies excluded (or included) in the base case 
were included (or excluded) in separate scenarios (online 
supplementary table 3). In csDMARD-IR, a scenario was 
tested to address the potential modifying effect of patient 
weight. Weight was selected as a potential modifier by 
first establishing the link via scatter plot and a trend, 
and then evaluating the regression and coefficient of R2 
between patient characteristics at baseline and ACR20. 
This process identified weight as a potential effect modi-
fier. However, meta-regression using average weight of 
the study as a variable was not possible due to the level of 
missing data for weight across the studies. Instead, those 
studies conducted in exclusively Asian populations were 
excluded in a scenario analysis. The basis of this exclu-
sion was that Asian ethnicity would serve as a proxy for 
populations with relatively lower weight than other popu-
lations.
In a separate scenario, the ATTRACT and SWEFOT 
studies were included in a scenario and mTSS at 52 weeks 
was examined; ATTRACT (and the connected SWEFOT 
study of interferon triple-combination therapy with two 
csDMARDs and methotrexate) was initially excluded 
in the base case due to a high mTSS at baseline. In an 
additional scenario in csDMARD-IR, TNFi were pooled 
together as a class; ACR outcomes were compared with 
the base case, which evaluated the TNFi individually. This 
scenario was evaluated to inform cost-effectiveness evalu-
ations of sarilumab.
Finally, a scenario analysis in the TNFi-IR population 
considered exclusion of the GO-AFTER study, which eval-
uated a mix of monotherapy and combination therapy.
ResulTs
literature search and selection
The literature search identified a total of 15 698 cita-
tions (figure 1) relevant to DMARD combination treat-
ments and monotherapies for RA. Three hundred and 
nine citations that met the screening criteria, reporting 
results of 108 trials, were retrieved. Of these, 87 RCTs 
were included in the SLR, but 32 were excluded based on 
the n<30 sample size or owing to not reporting outcomes 
of interest, invalid study design or not linked in network 
(including RACAT and Machado 2014 reported data on 
the outcomes of interest but could not be linked in the 
analyses networks; these were subsequently pooled with 
other TNFi studies in scenario analysis). RACAT was also 
excluded, as the control arm is not a single csDMARD but 
a combination of sulfasalazine and hydroxychloroquine. 
There were no equivalent controls from other RCTs.
A total of 46 RCTs (45 studies at week 24 and one study 
at week 52) were included for the csDMARD-IR popula-
tion and nine RCTs were included for the TNFi-IR popu-
lation for the present NMA in combination treatments 
(figure 1). These included the three sarilumab+csD-
MARD combination treatment RCTs: MOBILITY-A, 
MOBILITY-B and TARGET.
nMA evidence base
Although sarilumab has been evaluated in phase III 
studies across both csDMARD-IR and TNFi-IR patient 
populations, availability of data for the other compara-
tors varied across the two populations; most data were in 
csDMARD-IR patients, with fewer RCTs in the TNFi-IR 
setting, limiting the ability to accurately evaluate the 
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Figure 1 Systematic review and network meta-analyses study selection flow chart. *45 studies reporting outcomes at week 
24 and one study reporting outcome at week 52. csDMARD, conventional synthetic disease-modifying antirheumatic drugs; IR, 
inadequate responders; NMA, network meta-analyses; TNFi, tumour necrosis factor α inhibitors.
comparative efficacy of combination therapies in TNFi-
IR. For both patient populations, the networks for EULAR 
response were small and a high level of variability was 
observed in response rates between different studies and 
thus these results are not reported here. The networks 
for ACR response, with ACR20 in particular, were the 
most robust for both populations (figure 2) where most 
interventions were included in multiple trials. Based 
on previously published studies, high variation in the 
placebo response rates was observed across studies.14 24
Key features of patient demographics and baseline data 
from the selected studies are provided in table 2.
csDMarD-ir studies
Among 46 trials included in csDMARD combination 
population (online supplementary table 1), 29 were 
phase III trials, seven were phase II trials, two were phase 
II/III trials and eight did not mention trial phase. Study 
durations varied from 24 up to 52 weeks with several 
studies allowing for open-label extensions. In 33 studies, 
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Figure 2 Evidence base networks for American College of Rheumatology 20 outcomes at 24 weeks. Comi, combination; 
csDMARD, conventional synthetic disease-modifying antirheumatic drugs; IR, inadequate responders; MTX, methotrexate; 
TNFi, tumour necrosis factor α inhibitors.
patients had to have been on stable methotrexate for at 
least 12 weeks prior to entering the study, in four studies, 
this criterion was not required and in the rest of the 
studies, no information was reported. Sample sizes varied 
from less than 40 patients to more than 400 patients per 
randomised group. Rescue medication was permitted 
in 25 of the trials, not permitted in two trials and not 
reported in the remainder of the trials.
tnFi-ir studies
The TNFi-IR studies included seven phase III trials and 
one trial that did not mention the RCT phase (online 
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supplementary table 2). Study duration varied from 24 
up to 104 weeks. Sample sizes varied from 42 patients per 
arm to more than 200 patients per arm. Rescue medica-
tion was allowed in five of the trials and not reported in 
the remainder of the trials. Overall, eight studies reported 
ACR20/50/70 and HAQ-DI at 24 weeks (respectively) 
and were included in the NMA; the others included 
different endpoints that were not evaluated in this NMA.
Base case nMA results
NMA results for the csDMARD-IR and TNFi-IR popu-
lations are shown in tables 3 and 4 versus csDMARDs in 
the csDMARD-IR population, and superior efficacy was 
observed for sarilumab 200 mg and sarilumab 150 mg on 
all outcomes (table 3). Sarilumab 200 mg showed superior 
efficacy versus baricitinib 2 mg, tofacitinib and certolizumab 
combinations on 24 week mTSS, and similar efficacy versus 
baricitinib 4 mg, adalimumab, etanercept, golimumab, 
infliximab and tocilizumab combinations (all doses) on all 
other outcomes. Sarilumab 150 mg showed similar efficacy 
to all lower doses of targeted DMARD combinations on 
all outcomes. Rates of SI/SAE were similar for sarilumab 
150 mg and sarilumab 200 mg versus all comparators in 
csDMARD-IR.
In the TNFi-IR population (table 4), superior efficacy 
was observed for sarilumab 200 mg versus baricitinib 2 mg 
combination on ACR50 and DAS28<2.6 and versus abata-
cept, golimumab, tocilizumab 4 mg/kg IV and rituximab 
combinations on DAS28<2.6. On ACR20/50/70, similar 
efficacy was observed for sarilumab 200 mg compared 
with abatacept, golimumab, tocilizumab 4 mg and 8 mg/
kg IV and rituximab combinations. Sarilumab 150 mg had 
superior efficacy versus baricitinib 2 mg and rituximab 
combinations on DAS28<2.6, similar efficacy to all other 
bDMARD combinations (all lowest approved dose) on 
all outcomes and similar efficacy to tocilizumab 4 mg on 
ACR70; however, efficacy was lower versus tocilizumab 8 
mg on ACR20 and DAS28 remission. SAEs, including SIs, 
appeared similar for sarilumab 200 mg and 150 mg versus 
all comparators.
scenario analyses
In the csDMARD-IR scenario, which excluded six studies 
assessing Asian patients only, results were similar to the 
ACR20/50 base cases for sarilumab 200 mg against all 
comparators. However, sarilumab 200 mg was superior 
to tocilizumab IV 4 mg/kg combination for ACR70. For 
the scenario that included the ATTRACT and SWEFOT 
studies, sarilumab 200 mg combination therapy showed 
superiority to csDMARD and sarilumab 150 mg combi-
nation for mTSS at 52 weeks, and inferiority to inflix-
imab combination in the fixed-effects model. In the 
random-effects model, sarilumab 200 mg combination 
was comparable to all treatments. The scenario that 
pooled all 13 TNFi treatment interventions from the 
43 studies included in the csDMARD-IR network, sari-
lumab 200 mg combination therapy was found to be 
superior to csDMARDs and comparable to all other 
combination therapies. The scenario in the TNFi-IR 
population excluding the GO-AFTER study obtained 
results consistent with the base case for sarilumab 200 mg 
against all the comparators except for golimumab combi-
nation on ACR20/70.
dIsCussIOn
Active comparator controlled, randomised trials evalu-
ating the comparative efficacy and safety of bDMARDs 
or tsDMARDs are few and limited to adalimumab as an 
active comparator.4 25–29 In the absence of head-to-head 
trial evidence, indirect comparison through a NMA 
provides best estimates of comparative efficacy. NMA also 
provides fully conditional estimates of relative treatment 
effect. This NMA was undertaken to compare sarilumab 
versus relevant csDMARD, bDMARD and tsDMARD 
comparators in csDMARD-IR and TNFi-IR adult RA 
patient populations.
In the csDMARD-IR network, sarilumab showed signifi-
cantly better efficacy versus csDMARDs, consistent with 
the head-to-head evidence from MOBILITY-B, and similar 
efficacy and safety to combination therapies including all 
licensed biologics, and the tsDMARDs tofacitinib and 
baricitinib. Typically, safety outcomes presented broad 
credible intervals due to their relatively low occurrence.
Sarilumab showed significantly better efficacy versus 
csDMARD in the TNFi-IR population, consistent with 
the head-to-head evidence from TARGET and compa-
rable efficacy and safety to other biological regimens for 
most outcomes. Both doses of sarilumab showed favour-
able outcomes on ACR50 and on DAS28 remission in 
the TNFi-IR population compared with combination 
therapies with baricitinib and tocilizumab and all other 
bDMARDs and tofacitinib.
strengths and limitations
There are considerable challenges in undertaking an 
NMA when there is heterogeneity in the placebo arms 
across trials. Variability in placebo response was observed 
across both csDMARD-IR and TNFi-IR networks. Some 
degree of variation in patient characteristics across studies 
is an inevitable feature of the RA evidence base given 
the evolution of clinical trial design and patient popu-
lations over the 20-year period since the first biological 
trials. Furthermore, geographic location may be another 
potential confounding factor in RA clinical trials. There 
are also key differences in the inclusion/exclusion of 
studies. If these characteristics are effect modifiers of 
the relative treatment effects of interest, the heteroge-
neity of the evidence base15 23 30 can limit the validity of 
indirect comparisons. Therefore, a scenario analysis was 
conducted to test weight as a potential modifier.
In addition, a high level of heterogeneity of response 
in the placebo arms of studies (ie, placebo+csDMARDs 
in combination studies) has been previously noted by 
NICE, using certolizumab pegol in RA as an example,19 
where the treatment effect expressed as log ORs had a 
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negative relationship with the baseline risk.14 24 This is 
an issue that can particularly limit indirect comparisons. 
One explanation for heterogeneity in placebo arms of 
recent studies may be that more recent trials in RA have 
included larger proportions of patients from the Latin 
American region, whereas earlier trials included a higher 
proportion of patients from North America and Western 
Europe. For the Latin American region, higher response 
rates in RA have been noted by NICE in the placebo arm 
as well as the active arm, compared with other regions.19 
This phenomenon was also observed in the phase III 
MOBILITY and TARGET trials for sarilumab and other 
RA trials, including the GO-FORWARD trial of golim-
umab and the tocilizumab trials. Several reasons could 
account for regional variation, including differences in 
background and prior care, differences in patient concep-
tualisation of PRO components of outcome measures 
and differences in physician approach to practice. In the 
present study, variation in the placebo responses across 
studies were addressed by applying alternative analytical 
methods. We attempted to address this issue within the 
NMA methodology, as baseline risk regression has been 
suggested as a solution to this and has been previously 
used in RA.19 20 31 It performs well when there is a large 
number of trials in a network, as in the csDMARD-IR 
population.
An additional challenge was met for the smaller 
TNFi-IR network. While sparse data preclude a number 
of analytic options, including meta-regression, NMA on 
risk difference is a promising strategy to address this 
limitation.14 The TNF-IR outcome networks were small 
(with at most seven studies) and it was therefore difficult 
to obtain model convergence and precise estimation 
by following the REM approach. To address this issue, 
less vague priors were used: (1) for relative treatment 
effect, called log-odds (under the belief of OR=(0,500), 
d~Normal (0,10)) and study effect (under the belief 
of p=(0.005, 0.995), mu~Normal (0,10)) based on the 
work of Spiegelhalter and colleagues for coefficient 
of regression.32 Therefore, it was estimated from BR of 
ACR20/50/70 in csDMARD-IR with variance less than 
1 (SD=(0.13;0.85)) and with the mean of 0 in order to 
give the chance for both negative and positive sides: 
B~Normal (0,1), between study SD also decreased grad-
ually in uniform distribution. However, even with infor-
mative priors, very wide credible intervals were obtained; 
BR-NMA results for the TNF-IR population were highly 
uncertain (eg, OR of ACR20 of sarilumab 200 mg combi-
nation versus csDMARDs observed in the TARGET trial 
was 3.28 with 95% CI 2.11, 5.12, while the NMA regres-
sion result was 2.50 with 95% CI 0.82, 6.78).
Thus, in the present NMA, the RD-NMA models 
worked well, even in a situation with few studies or in the 
case of rare events (eg, SI or SAE) and predicted data 
well, with a higher degree of certainty than the BR-NMA. 
We confirmed the reliability of this approach by recon-
ducting analyses for the ACR20/50/70 networks using a 
probit random-effect model and informative priors19 20 31 
for the between-study variance (log normal with mean 
−2.56 and variance of 1.74*1.74, proposed by Turner et 
al (2012),33 and results were consistent with RD-NMA 
models.
Finally, we faced a situation whereby different dosing 
regimens for some drugs were evaluated across studies. 
To solve this issue, the authors first assessed the over-
lapping of CIs of the individual studies. In most cases, 
there was overlap, therefore, these studies were pooled, 
and the validity of this approach was justified via clin-
ical input. However, in the one case where there was 
no overlap, tocilizumab 25 mg two times a week versus 
tocilizumab 50 mg once a week, clinical input informed 
the decision to pool these comparable regimens.
The robustness of this NMA derives from exploration 
and application of rigorous methods to account for 
heterogeneity and also inclusion of up to date evidence 
including new bDMARDs sarilumab and the tsDMARD 
baricitinib. A range of efficacy and safety outcomes 
also provided a comprehensive picture of comparative 
efficacy and safety of sarilumab in the csDMARD-IR 
and TNFi-IR populations, to inform clinical deci-
sion-making and conduct of health technology assess-
ments. The most robust networks, ACR20/50, used 
only one common comparator on all comparisons with 
sarilumab on these endpoints. Moreover, there was no 
major concern of inconsistencies given that the appro-
priate models were implemented; so, for outcomes with 
plentiful studies, as in the csDMARD-IR population, the 
results were considered robust. Four scenario analyses 
confirmed the results against the base case analysis, 
where comparisons were feasible.
Many NMAs have been published in RA, which 
differed in their precise aims, inclusion criteria, anal-
yses performed and results. Thorlund and colleagues34 
reviewed 13 published NMAs and despite similar stated 
eligibility criteria and objectives, found differences in 
the estimated treatment effects, the inclusion of trials, 
analytic approaches and endpoints evaluated. For 
example, some studies report DAS28-ESR and others 
report DAS28-CRP. In the present NMA, we examined 
both outcomes, although the variability in outcome 
definition may have impacted the DAS28 results and so 
it may not be appropriate to compare fully the results 
of this NMA with previously published NMAs. However, 
published NMAs have shown similar efficacy and safety 
between different biological drugs for the majority of 
comparisons14 34 and the results of the present NMA for 
those biologics are in line with these findings.
In the present NMA, there were limitations to the 
conclusions that could be made for the efficacy of sari-
lumab versus use of a further TNFi in TNFi-IR patients 
due to the very limited evidence base. The only trial that 
could be included was the GO-AFTER trial, in which 
only ~58% patients had failed their previous TNFi 
because of lack of efficacy. This percentage is lower 
than the other included studies in which almost 100% 
of patients had failed a previous TNFi due to lack of 
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efficacy (eg, TARGET, 92.3%). Therefore, the conclu-
sions regarding the relative efficacy and safety of sari-
lumab (or other non-TNFis) versus TNFis in TNFi-IR 
patients should be interpreted with caution.
Nonetheless, this NMA was conducted following 
best practice guidelines and demonstrated that sari-
lumab SC at both 150 mg and 200 mg doses in combi-
nation with csDMARDs or methotrexate has superior 
efficacy compared with csDMARDs alone and compa-
rable or better efficacy compared with other biological 
and targeted synthetic combination therapies in both 
csDMARD-IR and TNFi-IR patient populations. Sari-
lumab 150 mg and 200 mg had parity efficacy and safety 
to tocilizumab 4 mg and 8 mg/kg intravenously. SAEs 
including SIs appeared similar for sarilumab 150 mg 
and 200 mg versus all comparators.
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